In majority, the disorder involves deficient or absent synthesis of the β‐globin chains that constitute hemoglobin molecules and results in chronic hemolytic anemia. Relapse is the main cause of treatment failure in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and limits the curative potential of allogeneic blood stem cell transplantation (allo‐HCT). Indolent B‐NHLs, such as follicular lymphoma (FL), although not generally considered curable may be treated over many years with good prognosis. Additional chromosomal abnormalities are common in Ph+ ALL and have a varying impact on prognosis; some adverse, others less so. The establishment of an institutional GVHD adjudication committee enabled standardized assessment of GVHD. To minimize the risk of infection in transplantation, we focused on preventive measures and strict screening in each section of transplantation, involving healthy donors, recipients, caregivers and medical workers. Prompt recognition of toxic effects and rapid intervention are essential in the management of patients receiving CAR T‐cell therapy. Although xenotransplants were described in an ancient Irish manuscript, it was not until adverse hematological effects of ionizing radiation were known during World War II that the stimulus for bone marrow transplantation was established. Our workflow can be adopted by other centers to create a similar framework for dedicated GVHD evaluation. However, a subset of B‐NHLs can undergo histologic transformation into more aggressive subtypes with outcomes similar to aggressive B‐NHLs. Clearly, other genes or mutations are in place that affect the outcome of Ph+ ALL. In this review, we will discuss the indications and outcomes of allogeneic transplant for patients with CML in the modern era. Such IL‐18 TRUCKs or “4th generation” CAR T cells are going to change our concepts of treating tumors and delivering drugs to predefined lesions in the near future. Recently, the anti‐CCR4 antibody mogamulizumab (Moga, Kyowa Hakko Kirin Co., Ltd, Tokyo, Japan) was approved as a treatment for CCR4‐positive adult T‐cell leukemia‐lymphoma (ATL) in Japan. Adoptive therapy with chimeric antigen receptor (CAR)‐modified T cells achieved remissions of so far refractory leukemia/lymphoma; however, the treatment of solid tumors still remains challenging. Clinical implication January 2020. Clinical trials document that this form of immunotherapy can induce lasting remissions of hematologic malignancies; however, the successes could not yet be transferred to the treatment of solid tumors. In addition to the 2-year Journal Impact, the 3年インパクトファクター can provide further insights into the impact of Advances in Cell and … We evaluated the univariate association between variables of interest and OS and RFS using the log‐rank test. High dose therapy followed by autologous hematopoietic cell transplant (AHCT) is an integral component of myeloma therapy in eligible patients2. GVHD is a frequent complication following allo‐HCT. There is no widely agreed standard of care for the first line therapy of FL. In this review these genetic aberrations will be considered in some detail. These drugs have extended overall survival (OS) up to 12 years. The recent understanding that NK cells share developmental and homeostatic properties with T cells led to the hypothesis that NK cells should be able to elicit an (antigen‐specific) recall response and should as such theoretically confer the potential for self‐renewal and clonal expansion which may translate into longevity. Graft‐versus‐host (GVHD) is an important cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). ETP‐ALL is a high‐risk subgroup of T‐ALL that is characterized by stem‐cell‐like features, absence of NOTCH pathway mutations, and resistance to chemotherapy. All rights reserved. Potential mitigation strategies for this include a closer level of oversight or hiring a patient blood manager to provide real time metrics. Integrin αvβ3 is expressed in several tumour entities including melanoma, glioblastoma, breast, pancreatic and prostate cancer, where it promotes tumour cell survival and metastasis.